Patents Examined by Christine Nucker
-
Patent number: 5643576Abstract: A method of protecting a subject against a disease comprises administering a recombinant Venezuelan Equine Encephalitis (VEE) virus to the subject in an effective immunogenic amount, with the VEE virus containing a heterologous DNA segment, and with the heterologous DNA segment comprising a promoter operable in the subject operatively associated with a DNA encoding an immunogenic protein or peptide effective for protecting the subject from the disease. Preferred promoters are VEE 26S subgenomic promoters, and preferred immunogens are viral immunogens. Novel attenuating mutations useful in carrying out the invention are also disclosed.Type: GrantFiled: May 19, 1995Date of Patent: July 1, 1997Assignee: The University of North Carolina at Chapel HillInventors: Robert E. Johnston, Nancy L. Davis, Jonathan F. Smith, Franziska B. Grieder
-
Patent number: 5236826Abstract: An immunoassay method for the detection or quantitation of an analyte suspected of being in a solution comprising: (a) combining said specimen, a first binding component, insoluble particles, and second binding component labelled with a signal generating material in a solid phase retention and separation apparatus having a sufficient pore size such that said particles are trapped within said filter yet permitting rapid passage of fluid therethrough in such a manner that an immunological reaction occurs if analyte is present in said specimen, resulting in the formation of an immunocomplex of insolubilized first binding component:analyte:second labelled binding component on or within said filter means; (b) separating bound from unbound material; and (c) determining the presence and/or amount of signal produced which is correlative with the amount of analyte present in the solution.Type: GrantFiled: December 18, 1990Date of Patent: August 17, 1993Assignee: Murex CorporationInventor: David L. Marshall
-
Patent number: 5234815Abstract: Antibodies having specific binding affinity for substantially pure, isolated, thyroid hormone binding protein (p58) are described.Type: GrantFiled: February 21, 1991Date of Patent: August 10, 1993Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Sheue-yann Cheng
-
Patent number: 5229492Abstract: Protein G variants are disclosed. These protein G variants have the immunoglobulin binding properties of protein G. Also disclosed is the preparation of the protein G variants by expression from hosts transformed with a gene encoding the protein G variants.Type: GrantFiled: June 19, 1990Date of Patent: July 20, 1993Assignee: Pharmacia LKB Biotechnology ABInventor: Stephen R. Fahnestock
-
Patent number: 5223427Abstract: Murine hybridomas producing monoclonal antibodies capable of immunoreacting with huTFh and polypeptide analogs are described. Also contemplated are immunologic methods for detecting huTF heavy chain in body fluid, detecting thrombic events in vivo, isolating coagulation factor, and neutralizing VII/VIIa coagulation factor binding in vivo.Type: GrantFiled: March 9, 1988Date of Patent: June 29, 1993Assignee: The Scripps Research InstituteInventors: Thomas S. Edgington, James H. Morrissey
-
Patent number: 5221612Abstract: The present invention involves a method for detecting bladder cancer in a subject. The method preferably comprises first collecting a urine sample from the subject. The presence of a proteinaceous substance having a molecular weight of about 180 kDa according to its relative electrophoretic migration rate through detergent-containing polyacrylamide gel is then measured. This substance reversibly binds concanavalin A and is complexed with gamma globulin while in the urine. The gamma globulin complex binds to Staphlococcal protein A. Said proteinaceous substance, when present in detectable amount, is an indicator of bladder cancer.The method of the present invention for diagnosing bladder cancer in a subject may also be described as comprising detection in a urine sample from said subject of a proteinaceous substance having a molecular weight of about 180 kDa and being unreactive with antibodies specifically binding to carcinoembryonic antigen or epidermal growth factor receptor.Type: GrantFiled: March 3, 1989Date of Patent: June 22, 1993Assignee: Board of Regents, The University of Texas SystemInventors: Haiyen E. Zhau, Richard J. Babaian
-
Patent number: 5217861Abstract: Protein compositions containing proteins of the lymphadenopathy virus, which compositions are used for diagnosis of antibodies of such protein in biological fluids, especially blood serum, for the detection or absence of infection. Such compositions contain typically the p18, p13 and/or p25 proteins.Type: GrantFiled: February 12, 1988Date of Patent: June 8, 1993Assignee: Institut PasteurInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Vezinet-Brun, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Theresa Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret
-
Patent number: 5204239Abstract: Biosensors for qualitative and quantitative analysis comprise an amphipathic liquid crystalline membrane composed of a lipid bilayer attached to a recording electrode via bridging anchoring molecules. The lipid bilayer is doped with biologic or synthetic ion channels and is in continuous contact with a bulk aqueous medium on both its surfaces. The bridging anchoring molecules may contain a phospholipid moiety linked to a polyoxylakylene chain terminated with a thiol or thioether residue.Type: GrantFiled: January 9, 1991Date of Patent: April 20, 1993Assignee: Yeda Research and Development Co., Ltd.Inventors: Carlos Gitler, Itzhak Yuli
-
Patent number: 5194425Abstract: The invention is directed to methods and materials useful in treating autoimmune diseases. The therapeutic agents are of the formula X.sup.1 MHC.sup.2 peptide or MHC.sup.2 peptide.sup.1 X wherein X represents a functional moiety selected from a toxin and a labeling group; MHC is an effective portion of the MHC glycoprotein, said glycoprotein dissociated from the cell surface on which it normally resides; and "peptide" represents an antigenic peptide sequence associated with an autoantigen; .sup.1 represents a covalent bond or a linker bound to X and MHC or to X and peptide by covalent bonds; and .sup.2 represents a covalent bond, a noncovalent association, or a linker covalently bound to or associated with the MHC and peptide. These complexes can be used to target helper T-cells which are specifically immunoreactive with autoantigens.Type: GrantFiled: June 21, 1989Date of Patent: March 16, 1993Assignee: Anergen, Inc.Inventors: Somesh D. Sharma, L. Bernard Lerch, Brian R. Clark
-
Patent number: 5180660Abstract: Disclosed are immunologically active polypeptides, preferably antibodies or antibody fragments, and most preferably monoclonal antibodies, which are reactive with idiotypes of antibodies to human lymphocyte T4 protein and are reactive with the HIV virion in a manner allowing for in vitro and in vivo neutralization of HIV infectivity and detection of HIV particles in biological fluids. Presently preferred embodiments comprise monoclonal anti-monoclonal-anti-human lymphocyte T4 antibodies produced by new murine hybridoma cell lines JT4C8, JT4C12, JT4C16, JT1-1F3, JT1-1F3-E5, JT1-1D7 and JT2-N15. Also disclosed are active and passive vaccination procedures.Type: GrantFiled: March 13, 1991Date of Patent: January 19, 1993Assignee: Nissin Shokuhin Kabushiki KaishaInventor: Tsuneya Ohno
-
Patent number: 5175256Abstract: Novel labeling reagents are useful for radiolabeling proteins such as antibodies with radionuclide metals such as .sup.99m Tc, .sup.186 Re, and .sup.188 Re. The reagents are of the following formula: ##STR1## wherein: each X is independently chosen from O, S, NH, or NR.sub.2, wherein R.sub.2 is a protecting group or an electron withdrawing group;R.sub.1 represents a protecting group, wherein each R.sub.1 is a separate protecting group or the two R.sub.1 symbols are taken together to represent a single protecting group; andeach T is independently chosen from hydrogen, lower alkyl groups of from 1 to about 6 carbon atoms, electron withdrawing groups, and lower alkyl groups of from 1 to about 6 carbon atoms substituted with electron withdrawing group(s).Type: GrantFiled: September 28, 1990Date of Patent: December 29, 1992Assignee: NeoRx CorporationInventors: Sudhakar Kasina, Ananthachari Srinivasan, James Sanderson, Alan R. Fritzberg
-
Patent number: 5171840Abstract: An isolated receptor protein for human B cell stimulatory factor-2, capable of specifically binding to the human B cell stimulatory factor-2; DNA coding for the above-mentioned receptor protein; expression vectors containing the above-mentioned DNA; host organisms transformed with the above-mentioned expression vector; a process for production of the receptor protein comprising culturing the host organisms in a medium to produce the receptor protein and recovering the receptor protein from the culture; and a antibody reacting with the protein.Type: GrantFiled: January 19, 1989Date of Patent: December 15, 1992Inventor: Tadamitsu Kishimoto
-
Patent number: 5169752Abstract: Disclosed are immunologically active polypeptides, preferably antibodies or antibody fragments, and most preferably monoclonal antibodies, which are reactive with idiotypes of antibodies to human lymphocyte T4 protein and are reactive with the HIV virion in a manner allowing for in vitro and in vivo neutralization of HIV infectivity and detection of HIV particles in biological fluids. Presently preferred embodiments comprise monoclonal anti-monoclonal-anti-human lymphocyte T4 anti-bodies produced by new murine hybridoma cell lines JT4C8, JT4C12, JT4C16, JT1-1F3, JT1-1F3-E5, JT1-1D7 and JT2-N15. Also disclosed are active and passive vaccination procedures.Type: GrantFiled: March 13, 1991Date of Patent: December 8, 1992Assignee: Nissin Shokuhin Kabushiki KaishaInventor: Tsuneya Ohno
-
Patent number: 5165923Abstract: Disclosed are methods and compositions for the treatment of Hodgkin's disease and processes involving Hodgkin's disease cells or Reed-Sternberg cells, through specific elimination of Hodgkin's disease cells through the application of immunotoxin technology. The compositions of the invention include toxin conjugates composed of a Hodgkin's disease cell binding ligand conjugated to a toxin A chain moiety such as ricin A chain or deglycosylated ricin A chain, by means of a cross-linker or other conjugation which includes a disulfide bond. In preferred aspects of the invention, therapeutic amounts of conjugates composed of a CD-30 or IRac antibody or fragment thereof conjugated to deglycosylated A chain by means of an SMPT linker is administered to a Hodgkin's disease patient so as to specifically eliminate Hodgkin's disease cells without exerting significant toxicity against non-tumor cells. Also disclosed are particular hybridomas and monoclonal antibodies, and associated methodology, which may be employed, e.Type: GrantFiled: November 20, 1989Date of Patent: November 24, 1992Assignee: Imperial Cancer Research TechnologyInventors: Philip Thorpe, Andreas Engert
-
Patent number: 5159063Abstract: A substantially pure, single chain plasma protein of approximately 120 kDa having an N-terminal amino acid sequence EKNGIDIYSLTD, and a mixture of protein fragments having vasodilatory activity which fragments are generated by activated Kallikrein cleavage of the 120 kDa protein.Type: GrantFiled: February 2, 1989Date of Patent: October 27, 1992Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Carl H. Hammer, Ruth M. Jacobs, Michael M. Frank
-
Patent number: 5156951Abstract: The present invention comprises a method for detecting immunological changes in blood samples from patients infected with HIV. The method comprises the use of fluorescently labelled monoclonal antibodies against IL-2R (CD25). Other antibodies, including anti-CD3, anti-CD38 and anti-HLA DR antibodies also may be used. It has been found that a decrease in expression of CD25 in such samples indicates HIV infection.Type: GrantFiled: July 13, 1989Date of Patent: October 20, 1992Assignee: Becton Dickinson and CompanyInventors: Bruce A. Bach, Noel L. Warner, Anne Jackson
-
Patent number: 5155212Abstract: The present invention is directed to a fluorescence polarization assay for phencyclidine and phencyclidine derivatives, to the various components needed for preparting and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for making them, and a reagent kit containing them. The tracers and the immunogens are made from substituted phencyclidine compounds. A fluorescein moiety is included in the tracer, while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer.Type: GrantFiled: May 29, 1990Date of Patent: October 13, 1992Assignee: Abbott LaboratoriesInventors: Robert E. Dubler, Mary P. Frintner, Jonathan Grote, Gregg A. Hadley, David J. Hawksworth, Hal D. Hopkins, Daniel S. Nam, Frank S. Ungemach, Larry K. Wray
-
Patent number: 5151348Abstract: An enzyme-linked immunoassay for the determination of cyclosporin A levels in whole blood samples is provided based on the utilization of .beta.-D-galactosidase as an enzyme label and chlorophenol red-.beta.-D-galactopyranoside or resorufin-.beta.-D-galactopyranoside as a .beta.-D-galactosidase substrate.Type: GrantFiled: December 23, 1988Date of Patent: September 29, 1992Assignee: E. I. Du Pont de Nemours and CompanyInventors: Hon-Peng P. Lau, Warren K. Miller
-
Patent number: 5149783Abstract: This invention relates to a DNA molecule or a functional derivative thereof coding for a fusion protein, the fusion protein comprising an enzymatically active component and a non-enzymatically active polypeptide component which may be cleaved therefrom, an expression system which contains the DNA molecule, the use thereof as a test system for inhibitors of viral proteases, and an assay for identifying viral inhibitors.Type: GrantFiled: December 23, 1988Date of Patent: September 22, 1992Assignee: Boehringer Ingelheim International GmbHInventors: Wolfgang Sommergruber, Friederike Fessl, Ernst Kuechler, Dieter Blaas, Timothy Skern, Manfred Zorn, Markus Duechler, Heinrich Kowalski, Peter Volkmann, Ingrid Maurer-Fogy, Peter Pallai
-
Patent number: 5149528Abstract: Purified cytotoxic proteins for use within therapeutic compositions are disclosed. The proteins inhibit protein synthesis in vitro, exhibit abortifacient activity in mice, and contain proline residues with equivalent positions at residue 43 and residue 46 in ricin A-chain. A method for preparing such a cytotoxic protein from the tissue of Trichosanthes kirilowii is also disclosed. The proteins may also be used within a method for inhibiting protein synthesis in selected cells.Type: GrantFiled: November 13, 1989Date of Patent: September 22, 1992Assignee: ZymoGenetics, Inc.Inventors: John M. Maraganore, Wayne R. Kindsvogel